Related Experiment Video
Updated: Dec 10, 2025
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
New horizons from novel therapies in malignant pleural mesothelioma
Mutlay Sayan1, Swati Mamidanna2, Mehmet Fuat Eren3
1Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. ms2641@cinj.rutgers.edu.
Abstract:
Malignant pleural mesothelioma (MPM) is a relatively rare, but highly lethal cancer of the pleural mesothelial cells. Its pathoge-nesis is integrally linked to asbestos exposure. In spite of recent developments providing a more detailed understanding of the pathogenesis, the outcomes continue to be poor. To date, trimodality therapy involving surgery coupled with chemotherapy and/or radiotherapy remains the standard of therapy. The development of resistance of the tumor cells to radiation and several che-motherapeutic agents poses even greater challenges in the management of this cancer. Ionizing radiation damages cancer cell DNA and aids in therapeutic response, but it also activates cell survival signaling pathways that helps the tumor cells to overcome radiation-induced cytotoxicity. A careful evaluation of the biology involved in mesothelioma with an emphasis on the workings of pro-survival signaling pathways might offer some guidance for treatment options. This review focuses on the existing treatment options for MPM, novel treatment approaches based on recent studies combining the use of inhibitors which target different pro-survival pathways, and radiotherapy to optimize treatment.
Insights
Malignant pleural mesothelioma (MPM) is a lethal cancer linked to asbestos. This review explores novel treatments combining targeted pathway inhibitors with radiotherapy to overcome treatment resistance and improve outcomes for MPM patients.
Area of Science:
- Oncology
- Cancer Biology
- Asbestos-related Diseases
Background:
- Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer originating in the pleura, strongly associated with asbestos exposure.
- Despite advances in understanding its pathogenesis, patient outcomes remain poor, with trimodality therapy as the current standard.
- Tumor resistance to chemotherapy and radiotherapy presents significant challenges in MPM management.
Purpose of the Study:
- To review current therapeutic strategies for malignant pleural mesothelioma.
- To explore novel treatment approaches targeting pro-survival signaling pathways.
- To evaluate the potential of combining pathway inhibitors with radiotherapy for optimized MPM treatment.
Main Methods:
- Literature review of existing MPM treatments.
- Analysis of recent studies on novel therapeutic agents and combinations.
- Focus on the role of pro-survival signaling pathways in MPM resistance.
Main Results:
- Current trimodality therapy faces challenges due to tumor resistance.
- Ionizing radiation, while damaging cancer DNA, can activate pro-survival pathways.
- Targeting these pro-survival pathways offers a promising strategy to enhance treatment efficacy.
Conclusions:
- Understanding mesothelioma cell biology, particularly pro-survival pathways, is crucial for developing better treatments.
- Combining targeted inhibitors with radiotherapy may overcome resistance and improve therapeutic responses in MPM.
- Further research into these novel combinations is warranted to optimize clinical management.
More Related Videos
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...